Research graph
References from Pattern‐Based P53 Immunohistochemistry Predicts Recurrence in Colorectal Liver Metastases Without Complete Pathologic Response After Neoadjuvant Chemotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Global Burden of Colorectal Cancer in 2020 and 2040: Incidence and Mortality Estimates From GLOBOCAN
10.1136/gutjnl-2022-327736 · 2023 · External reference
Cost‐Effectiveness of New and Emerging Treatment Options for the Treatment of Metastatic Colorectal Cancer
2018 · External reference
Pattern of Distant Metastases in Colorectal Cancer: A SEER Based Study
10.18632/oncotarget.6130 · 2015 · External reference
Importance of Response to Neoadjuvant Chemotherapy in Potentially Curable Colorectal Cancer Liver Metastases
10.1186/1471-2407-8-120 · 2008 · External reference
Complete Pathologic Response After Preoperative Chemotherapy for Colorectal Liver Metastases: Myth or Reality?
10.1200/jco.2007.13.7471 · 2008 · External reference
The Characteristics and Long‐Term Survival of Patients With Colorectal Liver Metastases With Pathological Complete Response After Chemotherapy
10.7150/jca.47911 · 2020 · External reference
Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases
10.1200/jco.2008.17.5299 · 2008 · External reference
Pathological Response Grade of Colorectal Liver Metastases Treated With Neoadjuvant Chemotherapy
10.1111/j.1477-2574.2010.00170.x · 2010 · External reference
RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated With Chemotherapy Before Resection of Colorectal Liver Metastases
10.1245/s10434-014-4042-6 · 2015 · External reference
BRAF Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies
10.3390/cancers14174067 · 2022 · External reference
Targeting p53 Pathways: Mechanisms, Structures and Advances in Therapy
10.1038/s41392-023-01347-1 · 2023 · External reference
P53 Mutations in Colorectal Cancer—Molecular Pathogenesis and Pharmacological Reactivation
10.3748/wjg.v21.i1.84 · 2015 · External reference
Characterization of p53 Wild‐Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5‐Fluorouracil, Oxaliplatin, and Irinotecan
10.1158/1078-0432.ccr-03-0362 · 2004 · External reference
Clinical Significance of p53 Protein Expression and TP53 Variation Status in Colorectal Cancer
10.1186/s12885-022-10039-y · 2022 · External reference
Mutations in TP53 Are a Prognostic Factor in Colorectal Hepatic Metastases Undergoing Surgical Resection
10.1093/carcin/bgm012 · 2007 · External reference
Optimized p53 Immunohistochemistry Is an Accurate Predictor of TP53 Mutation in Ovarian Carcinoma
10.1002/cjp2.53 · 2016 · External reference
Immunohistochemical Investigation of Prognostic Biomarkers in Resected Colorectal Liver Metastases: A Systematic Review and Meta‐Analysis
10.1186/s12935-018-0715-8 · 2018 · External reference
The Prognostic Impact of RAS and TP53 Mutation According to Primary Tumor Location in Colorectal Liver Metastases
10.1200/jco.2021.39.15_suppl.3582 · 2021 · External reference
p53 Nuclear Protein Overexpression in Colorectal Cancer: A Dominant Predictor of Survival in Patients With Advanced Hepatic Metastases
10.1200/jco.1996.14.10.2696 · 1996 · External reference
Nuclear p53 Protein Expression in Resected Hepatic Metastases From Colorectal Cancer: An Independent Prognostic Factor of Survival
10.1016/s0959-8049(97)10165-4 · 1998 · External reference
P53 Mutation Analysis of Colorectal Liver Metastases: Relation to Actual Survival, Angiogenic Status, and p53 Overexpression
10.1158/1078-0432.ccr-04-2389 · 2005 · External reference
Assessing the TP53 Marker Type in Patients Treated With or Without Neoadjuvant Chemotherapy for Resectable Colorectal Liver Metastases: A p53 Research Group Study
10.1016/j.ejso.2015.02.003 · 2015 · External reference
Interleukin‐6 Increases Matrix Metalloproteinase‐14 (MMP‐14) Levels via Down‐Regulation of p53 to Drive Cancer Progression
10.18632/oncotarget.11243 · 2016 · External reference
A Role for p53 in the Regulation of Extracellular Matrix Metalloproteinase Inducer in Human Cancer Cells
10.4161/cbt.8.18.9207 · 2009 · External reference
Mutant p53 Gain‐Of‐Function Induces Epithelial–Mesenchymal Transition Through Modulation of the miR‐130b–ZEB1 Axis
10.1038/onc.2012.334 · 2013 · External reference
The Role of p53 in Anti‐Tumor Immunity and Response to Immunotherapy
10.3389/fmolb.2023.1148389 · 2023 · External reference
Regulation of Tumor Angiogenesis by p53‐Induced Degradation of Hypoxia‐Inducible Factor 1alpha
10.1101/gad.14.1.34 · 2000 · External reference
Mutant p53 in Cancer: From Molecular Mechanism to Therapeutic Modulation
10.1038/s41419-022-05408-1 · 2022 · External reference
Mutant p53 Drives Cancer Chemotherapy Resistance due to Loss of Function on Activating Transcription of PUMA
10.1080/15384101.2019.1688951 · 2019 · External reference
Coaltered Ras/B‐Raf and TP53 Is Associated With Extremes of Survivorship and Distinct Patterns of Metastasis in Patients With Metastatic Colorectal Cancer
10.1158/1078-0432.ccr-19-2390 · 2020 · External reference
Genomic and Prognostic Heterogeneity Among RAS/BRAF(V600E) /TP53 Co‐Mutated Resectable Colorectal Liver Metastases
10.1002/1878-0261.12885 · 2021 · External reference
The Pattern‐Based Interpretation of p53 Immunohistochemical Expression as a Surrogate Marker for TP53 Mutations in Colorectal Cancer
10.1007/s00428-024-03790-z · 2025 · External reference
